Voyager Therapeutics (VYGR) AI Stock Analysis

• Market Cap: $226.85M
• Dividend Yield: N/A
• Average Volume (3M): 378.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: -80.88%
• EPS Growth: -388.61%
• Country: US
• Employees: 172
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 55,600,082
• 10 Day Avg. Volume: 259,453
• 30 Day Avg. Volume: 378,155
• PEG Ratio: 0.04
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 4.09
• P/FCF Ratio: -17.36
• Enterprise Value/Market Cap: 0.46
• Enterprise Value/Revenue: 3.32
• Enterprise Value/Gross Profit: 3.32
• Enterprise Value/Ebitda: -0.78
• 1Y Price Target: $13.20
• Price Target Upside: 228.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -1.6
• Revenue Forecast (FY): $60.16M

• Rating: 46 Neutral
• Price Target: $4.00 ▼(-0.50% Downside)

The overall stock score of 46 reflects significant financial performance challenges, including declining revenues and profitability issues. Technical analysis indicates bearish momentum, and the negative P/E ratio highlights valuation concerns. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Strategic Collaborations

The collaboration with Transition Bio enhances Voyager's pipeline with potential treatments for ALS and FTD, leveraging innovative biomolecular approaches, which could lead to significant long-term revenue through milestone payments and royalties.

Cash Runway

Having a cash runway until 2028 provides financial stability and flexibility, allowing Voyager to focus on long-term strategic goals without immediate pressure to raise additional capital.

Innovative Platforms

The launch of the NeuroShuttle platform represents a significant innovation in nonviral delivery systems, potentially enhancing Voyager's competitive edge in gene therapy for neurological diseases.

Negative Factors

Revenue Decline

The significant decline in revenue poses a challenge to Voyager's financial health, potentially impacting its ability to invest in R&D and maintain competitive positioning in the biotechnology sector.

Profitability Issues

Ongoing profitability challenges, indicated by negative margins, may hinder Voyager's ability to reinvest in its business and sustain long-term growth, affecting overall financial performance.

Cash Flow Concerns

Insufficient cash flow generation to cover net income raises liquidity concerns, potentially limiting Voyager's operational flexibility and ability to fund future growth initiatives.

Voyager Therapeutics Business Overview & Revenue Model

Company Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Voyager Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments tied to the achievement of specific development goals, and royalties on product sales. Additionally, the company may receive funding from grants or government programs aimed at advancing research in gene therapy. Their revenue model is heavily dependent on the successful progression of their clinical trials and the commercialization of their therapies, as well as maintaining strong relationships with industry partners to enhance their product pipeline and potential market reach.

Voyager Therapeutics Financial Statement Overview

Summary

Voyager Therapeutics faces challenges in achieving consistent revenue growth and profitability, with negative profit margins and fluctuating cash flow metrics. Despite a low debt-to-equity ratio, the company needs to improve its return on equity and stabilize cash flows to enhance financial health.

Income Statement

Voyager Therapeutics has experienced significant revenue volatility, with a notable decline in revenue growth rate of -36.41% in the TTM period. The company maintains a high gross profit margin of 100%, but this is overshadowed by negative net profit, EBIT, and EBITDA margins, indicating ongoing operational challenges and profitability issues.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio of 0.165 in the TTM period, suggesting manageable leverage. However, the negative return on equity of -37.65% indicates that the company is not generating returns for shareholders. The equity ratio is not provided, but the overall financial position appears stable with room for improvement in profitability.

Cash Flow

Voyager Therapeutics has a positive free cash flow to net income ratio of 1.02 in the TTM period, indicating some efficiency in cash generation relative to net income. However, the operating cash flow is negative, and the free cash flow growth rate has fluctuated significantly, reflecting instability in cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.32M	80.00M	250.01M	40.91M	37.41M	171.13M
Gross Profit	31.32M	80.00M	157.84M	-14.86M	-36.37M	62.38M
EBITDA	-133.40M	-78.56M	126.45M	-39.65M	-68.45M	31.20M
Net Income	-126.78M	-65.00M	132.33M	-46.41M	-71.20M	36.74M
Balance Sheet
Total Assets	288.31M	393.05M	351.28M	159.36M	193.85M	261.58M
Cash, Cash Equivalents and Short-Term Investments	208.93M	266.68M	230.88M	118.85M	132.54M	181.14M
Total Debt	38.37M	43.73M	20.29M	23.13M	44.18M	47.61M
Total Liabilities	68.49M	93.29M	114.96M	100.34M	98.80M	107.26M
Stockholders Equity	219.82M	299.76M	236.32M	59.02M	95.06M	154.32M
Cash Flow
Free Cash Flow	-118.86M	-18.83M	74.66M	-15.00M	-55.13M	-108.81M
Operating Cash Flow	-116.73M	-15.31M	77.92M	-12.51M	-53.52M	-96.72M
Investing Cash Flow	50.82M	-94.86M	-141.64M	-7.34M	65.91M	113.00M
Financing Cash Flow	1.25M	114.02M	33.65M	1.11M	612.00K	3.16M

Voyager Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Negative. The current price of 4.02 is below the 20-day moving average (MA) of 4.17, below the 50-day MA of 4.22, and above the 200-day MA of 3.76, indicating a neutral trend. The MACD of -0.07 indicates Positive momentum. The RSI at 45.10 is Neutral, neither overbought nor oversold. The STOCH value of 55.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYGR.

Voyager Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLN	56 Neutral	$270.65M	-3.47	―	―	―	―
KYTX	55 Neutral	$453.61M	-2.34	-70.82%	―	―	-21.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYGR	46 Neutral	$226.85M	―	-46.09%	―	-80.88%	-388.61%
GALT	44 Neutral	$222.45M	-5.99	―	―	―	18.82%
TNYA	44 Neutral	$161.28M	-1.02	-96.44%	―	―	46.68%
RNAC	41 Neutral	$183.07M	-0.15	―	―	―	―